Doshi Dipal's Form 4 filing
Entrada Therapeutics, Inc. (TRDA) · filed May 20, 2024
- Accession no.
- 0001689375-24-000030
- Filed
- May 20, 2024
- Trade date
- May 16-17, 2024
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $45.1K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Doshi DipalCIK 0001613084 | Director, Officer (CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2024 | Common Stock | SSaleDisposed | −1,800 | $15.00 | −$27,000 | 338,575 | Direct | |
| May 17, 2024 | Common Stock | SSaleDisposed | −1,200 | $15.11 | −$18,132 | 337,375 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.